Remove DNA Remove Genome Remove Genomics Remove Life Science
article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 90
article thumbnail

Up to 8 recipients to be awarded grants for genomic research

Drug Discovery World

Beckman Coulter Life Sciences has released a call for registrations for its SPRI Grants for Genomic Research, which the company describes as part of its commitment to the next generation of researchers and scientists. . Applications will be accepted until 15 December 2022. .

Genome 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene Editing Innovations with Programmable Gene Insertion (PGI) Technology ft. John Finn, PhD, CSO, Tome Biosciences – Xtalks Life Science Podcast Ep. 160

XTalks

PGI is a cutting-edge gene editing technology that allows for the insertion of large sequences of DNA with site-specific precision. John Finn, PhD Chief Scientific Officer Tome Biosciences Dr. Finn has over 20 years of experience in the gene therapy space with a focus on genome editing and delivery technologies.

article thumbnail

Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China

The Pharma Data

NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Genome 52
article thumbnail

Illumina Partners with Sequoia Capital for its 3rd Life Science Incubator, This One in China

BioSpace

Illumina, the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

article thumbnail

Looking at Women’s Leadership in Life Science Industries on International Women’s Day

XTalks

On International Women’s Day, Xtalks is celebrating women’s leadership in the life sciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation. Challenges in Women’s Leadership.

article thumbnail

Illumina Partners with Sequoia Capital for its 3rd Life Science Incubator, This One in China

The Pharma Data

Illumina , the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.